The minimum dose required to cause infection of Romney and Suffolk sheep of the ARQ/ARQ or ARQ/ARR prion protein gene genotypes following oral inoculation with Romney or Suffolk a sheep Bovine spongiform encephalopathy (BSE)-derived or cattle BSE-derived agent was investigated using doses ranging from 0.0005g to 5g. ARQ/ARQ sheep which were methionine (M) / threonine (T) heterozygous or T/T homozygous at codon 112 of the Prnp gene, dosed ARQ/ARR sheep and undosed controls did not show any evidence of infection. Within groups of susceptible sheep, the minimum effective oral dose of BSE was found to be 0.05g, with higher attack rates following inoculation with the 5g dose. Surprisingly, this study found no effect of dose on survival time suggesting a possible lack of homogeneity within the inoculum. All clinical BSE cases showed PrPd accumulation in brain; however, following cattle BSE inoculation, LRS involvement within Romney recipients was found to be significantly lower than within the Suffolk sheep inoculated group which is in agreement with previous reports.
Citation: McGovern G, Martin S, Jeffrey M, Dexter G, Hawkins SAC, Bellworthy SJ, et al. (2016) Minimum Effective Dose of Cattle and Sheep BSE for Oral Sheep Infection. PLoS ONE 11(3): e0151440. https://doi.org/10.1371/journal.pone.0151440
Editor: Jason Bartz, Creighton University, UNITED STATES
Received: January 22, 2016; Accepted: February 29, 2016; Published: March 11, 2016
Copyright: © 2016 McGovern et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper.
Funding: This work was funded by the Department for Environment, Food and Rural affairs, grant numbers: SE1945, SE1846, received by SM and LG, respectively.
Competing interests: The authors have declared that no competing interests exist.
Transmissible spongiform encephalopathies (TSEs) or prion diseases are chronic, fatal, neurodegenerative diseases affecting humans and animals that may be acquired following oral exposure to the infectious agent. Thus, bovine spongiform encephalopathy (BSE) and variant Creutzfeldt-Jakob disease (vCJD) occurred as a result of the consumption of prion contaminated meat and bone meal  and BSE infected meat [2, 3], respectively. Similarly, kuru is associated with cannibalistic rituals  and chronic wasting disease and scrapie are also thought to be acquired orally [5, 6].
Sheep orally infected with cattle BSE show some features which are in common with naturally occurring cattle BSE, such as the accumulation of disease associated prion protein (PrPd) in the brain  and the biochemical properties of its protease-resistant core . However, BSE-infected sheep show a much wider distribution of PrPd and infectivity [9, 10] than cattle BSE [11–13], particularly within lymphoreticular system (LRS) tissues, and in this respect ovine BSE resembles natural scrapie.
Exposure of sheep to BSE-contaminated feed, together with the wide organ distribution of infectivity in BSE-infected sheep, raised concerns that BSE could be contagious and, like scrapie, have been maintained in the UK sheep flock while being masked by endemic scrapie. Certainly, a recent report on a large, long-standing experiment has shown that ovine BSE is contagious amongst sheep, albeit with a low degree of transmissibility . One caveat of that experiment was that the oral dose used to generate the parental flock was relatively high (5g of cattle BSE); this gave rise to considerations about lower doses being still infectious while resulting in longer survival times that could have allowed a more efficient natural transmission of BSE.
Therefore, determination of the minimum effective oral dose and the effect of dose on attack rate (AR) and survival time (ST) are essential for assessing the potential risk of BSE occurring in the UK sheep flock. In the studies reported here, we aimed to identify differential features between ovine BSE resulting from oral infection with either cattle- or sheep-derived BSE in sheep of two different breeds but the same susceptible prion protein gene (PRNP) genotype, and to assess the effect of dose on such features. Partial and preliminary results from these experiments, involving a limited number of sheep and dealing with the differential immunohistochemical (IHC) and biochemical features of the disease in comparison with natural scrapie, have been reported previously . The present report provides the final overall outcome of the experiments and concentrates on clinical parameters, AR and ST, and on tissue distribution of PrPd.
Materials and Methods
All animal experiments were approved by the local ethics committee of the Animal and Plant Health Agency (formerly Veterinary Laboratories Agency) and carried out in accordance with the Animals (Scientific Procedures) Act 1986 under Home Office license numbers 70/5780 and 70/5781. Sheep were sourced from a New-Zealand-derived, classical TSE-free flock (ARSU flock, APHA/Defra, UK); all male sheep were castrated.
In the first experiment, 50 Romney sheep (G1; 19 male and 31 female) and 50 Suffolk sheep (G2; 37 male and 13 female), (G2) of the ARQ/ARQ PRNP genotype (A, alanine, R, arginine and Q, glutamine at codons 136, 154 and 171 of PrP, respectively) were orally dosed at three and six months of age, respectively, with the same cattle-derived BSE inoculum (brain pool from clinically affected, BSE-confirmed cattle), as used in a previously described experiment . Each group was divided into five subgroups of 10 sheep each, which received 10-fold dilutions (5g to 0.0005g) of such inoculum and another 10 sheep of each breed (8 male and 2 female Suffolk sheep and 4 male and 6 female Romney sheep) were kept as age-matched, undosed controls (Table 1).
In the second experiment, three sheep BSE-derived inocula were used to orally challenge groups of 25 six month-old sheep of the same two breeds; each group was divided into subgroups of five sheep each which received one of the five different doses (5g to 0.0005g). The experimental groups were: 1) ARQ/ARQ Romney (G3; 25 female), ARQ/ARQ Suffolk (G4; 13 male and 12 female) and ARQ/ARR Romney sheep (G5; 25 male), which received a first passage Romney sheep BSE-derived inoculum (brain pool from clinically affected sheep of the experiment reported by McGovern et al. ), 2) ARQ/ARQ Romney (G6; 10 male and 15 female), and ARQ/ARQ Suffolk sheep (G7; 14 male and 11 female), which were dosed with a first passage Suffolk sheep BSE-derived inoculum (from the same experiment as indicated above) and 3) a further group of ARQ/ARQ Romney sheep (G8; 12 male and 13 female), which received a second passage Romney sheep BSE-derived inoculum (brain pool from clinically affected sheep of G3 above). Ten ARQ/ARQ Romney sheep (4 male and 6 female), and Suffolk sheep (8 male and 2 female) and 5 ARQ/ARR male Romney sheep remained as age-matched, undosed controls for the different experimental groups (Table 1). All inocula were prepared in 10 ml of phosphate saline buffer and administered by syringe in the back of the throat to ensure full swallowing.
All experimental groups were kept separate throughout the experiments in purpose built accommodation and husbandry and handling practices were set up to minimize chances of cross-contamination between groups. Bedding consisted of wood shavings which were replenished / removed as necessary to ensure dry bedding was maintained and the sheep were offered forage ad libitum supplemented with an appropriate quantity of concentrate. Sheep were vaccinated with heptavac P and treated regularly with doramectin, in addition to quarterly foot trim and bathing, and twice yearly shearing. Sheep were subject to clinical monitoring including standard daily observations, monthly bodyweight measurement and condition scoring, and monthly scratch response testing, and were euthanized using sodium barbiturate when they reached a clinical end point with signs characteristic of a TSE, as previously reported  or at the termination of the experiments. Some sheep died spontaneously (n = 2) or were euthanized (n = 6) as a result of intercurrent disease (Table 1) and were excluded from the study either because they died earlier than the average survival time of their corresponding subgroup or, in the case of subgroups with zero attack rate, because they survived for less than 1,500 days after dosing.
A retrospective, full PRNP open reading frame genotyping was conducted at the end of the studies and some Suffolk sheep (Table 1) were found to be MT or TT at codon 112 of PRNP (M, methionine and T threonine); they were not considered in the calculations of ARs and STs in view of the reported resistance of such sheep to oral BSE [10, 17].
At post-mortem, samples of brain, enteric nervous system (ENS; jejunum and ileum), cranial mesenteric ganglion (CMG) and selected LRS tissues (retropharyngeal, prescapular, distal jejunal and prefemoral lymph nodes, palatine tonsil, spleen and jejunal and ileal Peyer's patches) were collected and placed into 10% formaldehyde for IHC examinations. Following paraffin wax embedding, 4μm tissue sections were cut and immunolabelled using monoclonal PrP antibody R145 (APHA, Weybridge, UK) by procedures described elsewhere .
Once sheep dying from intercurrent disease are excluded as explained above (n = 8, with survival times of 591±224 days post-inoculation (dpi; average±standard deviation), evidence of BSE–both clinical disease and IHC detection of PrPd–was completely absent from the following sheep and experimental groups: 1) the 22 dosed ARQ/ARR sheep from G5 culled at 2475±413 dpi, 2) the 24 M112T or T112T dosed Suffolk sheep from G2, G4 and G7 culled at 2463±287 dpi, 3) the 45 undosed controls culled at 2654±118 days of age and 4) 78 ARQ/ARQ sheep from any groups dosed with 0.005g or 0.0005g and culled at 2458±235 dpi.
Therefore, the analysis of differences in AR is circumscribed to 118 sheep of the 295 of the whole experimental set up, that is, those dosed with 5g, 0.5g or 0.05g, which were not excluded because of intercurrent disease or PRNP genotype issues. Statistical analyses of differences in AR between the different groups were done by Fisher's exact test. When comparing sheep inoculated with the different inocula and considering the three doses together, no differences were observed between cattle- (21/51, 41.2%) and the three different sheep-derived BSE inocula (Romney 1st passage 9/27, 33.3%; Romney 2nd passage 5/14, 35.7%; Suffolk 1st passage 16/26, 61.6%); the only comparison that yielded nearly significant differences was between sheep dosed with Suffolk and Romney 1st passage inocula (P = 0.056). Equally, no differences between inocula were observed when considering the three doses separately (Table 2). No differences in AR were found between the two recipient breeds, with Romney and Suffolk sheep showing similar overall figures (30/73, 41.1% and 21/45, 46.7%, respectively); this absence of difference was maintained when the analyses were split by dose (Table 2).
Infectious titers of the four different inocula were calculated using the Reed-Muench formula . These, expressed as 1x (oral) ID50/g, were estimated as 1x10-0.14 for the cattle inoculum, 10−0.20 for the Romney sheep-derived inoculum (identical for first and second passage) and 100.46 for the Suffolk sheep-derived inoculum.
ARs were clearly influenced by the dose of inoculum administered, so that the 5g dose produced higher attack rates than the 0.5g and, particularly, the 0.05g doses. This was true when the comparison was made for all 118 sheep (5g, 33/41 [80.5%]; 0.5g, 13/39 [33.3%]; 0.05g, 5/38 [13.2%]; P<0.0001 in the two comparisons), when the analysis was carried out for the two recipient breeds (combined inocula) and within sheep dosed with cattle inoculum (Table 2). In the case of sheep dosed with the three different ovine BSE sources, those dosed with 0.5g showed non-significantly lower attack rates than those dosed with 5g. Differences were more subtle when comparing the 0.5g and the 0.05g, insofar as they were not significant in any of the analyses performed (Table 2). If in view of the absence of any difference, the 0.5g and 0.05g groups are merged together, then the differences between the 5g group and the merged group become significant in all analyses (results not shown but can be inferred from data presented in Table 2).
Comparative analyses of STs were restricted to the 51 sheep developing clinical BSE confirmed by IHC examination at post-mortem; the other 67 sheep considered in the AR were culled in the absence of clinical disease and of IHC evidence of infection at 2495±189 dpi. Since the differences in ARs were minimal and the number of affected sheep small, the data from the 0.5g and 0.05g doses were pooled together; for the same reasons the three sheep-derived BSE inocula were merged into one. Because the data were in most cases not normally distributed, the analyses were done by the non-parametric Mann-Whitney test. No differences in ST were observed between sheep given cattle- or sheep-derived BSE, either in the overall analysis (918±279 dpi v’s 842±227 dpi, respectively) or when the data were split by the two dose groups (statistical analyses not shown but can be inferred from data presented in Figs 1 and 2). Survival times were also similar for the two recipient breeds regardless of whether the analysis was done for all doses combined (881±274 dpi for Romney vs 863±216 for Suffolk sheep), or separately within the 5g and 0.5/0.05g doses, with the exception indicated below (statistical analyses not shown but can be inferred from data presented in Figs 1 and 2).
Attack rates (%), black bars inside white boxes, with actual values next to them. Survival times are indicated as average±SD dpi (age in case of undosed controls). Note that despite the marked differences in AR between the 5g and the 0.5/0.05g doses, STs are very similar with the only significant difference marked as * (for details refer to text).
Survival curves of sheep that developed IHC-confirmed BSE according to: a) source and dose of inoculum: dark blue, sheep inocula at 5g dose; light blue, sheep inocula at 0.5/0.05g dose; red, cattle inoculum at 5g dose; orange, sheep inocula at 0.5/0.05g dose. b) recipient breed and dose of inoculum: dark green, Suffolk sheep dosed with 5g; light green, Suffolk sheep dosed with 0.5/0.05g; purple, Romney sheep dosed with 5g; pink, Romney sheep dosed with 0.5/0.05g. Note that in both graphs, most sheep succumbed between ~600 and 1,150 days regardless of dose received and that the few sheep that survived for longer than ~1,150 days did so also regardless of the dose they received.
The dose of inoculum did not have a relevant impact on the STs of the affected sheep. Thus, in the overall analysis, sheep dosed with 5g had a marginally shorter survival time than those given 0.5g/0.05g (855±234 dpi and 906±281 dpi, respectively; P = 0.7). This lack of any difference was also patent when performing the analyses separately within the cattle and sheep derived inocula or within the Romney recipients (statistical analyses not shown but can be inferred from data presented in Figs 1 and 2). The only significant difference was found when analyzing the group of Suffolk sheep recipients in which sheep dosed with 0.5g/0.05g (n = 6) showed longer survival times (969±176 dpi) than those dosed with 5g (n = 15; 820±221 dpi; P = 0.04).
All 51 clinical BSE cases were positive by IHC in brain and, with two exceptions, showed widespread PrPd accumulation in the ENS and CMG. The exceptions were two Suffolk sheep, one dosed with Suffolk-derived inoculum, which was negative in the jejunal ENS and in the CMG, and another dosed with cattle BSE, which was negative in the jejunal ENS. All these 51 sheep were also positive in variable proportions of the LRS tissues examined. Thus, sheep dosed with 5g of the different sheep-derived BSE inocula were positive in ~79% (G7), ~83% (G8), ~92% (G6), ~93% (G3) or 100% (G4), while all sheep dosed with 0.5g or 0.05 were positive in all LRS tissues examined (Table 3). Following cattle BSE inoculation, LRS involvement within the Romney recipients (G1; ~76% for the three doses combined) was found to be significantly lower (P<0.0001) than within the Suffolk sheep (G2; ~98% for the three doses combined) inoculated group (Table 3). The IHC features of PrPd accumulation in the different tissues and systems of some of the clinically affected sheep of these experiments have been reported previously ; those that were not included in that report showed the same, BSE-characteristic features.
In terms of influence of the sheep host PRNP genotype on the susceptibility to TSEs, these experiments have confirmed previous reports and have brought up some new insights. On one hand the resistance of codon 112 threonine homo- and hetero-zygotes to oral BSE, confirms the findings of previous studies with respect to cattle-derived inocula [10, 17] and show that such resistance is maintained for sheep-derived inocula. On the other hand, allowing for the relatively small number of sheep examined, the resistance of ARQ/ARR sheep to sheep-derived BSE contrasts with the reported sensitivity of sheep of this genotype to oral dosing with sheep scrapie with a same 5g dose . It is unlikely that this discrepancy is due to scrapie being more infectious for sheep than BSE, since other experiments have shown that, for ARR/ARR sheep intracerebrally challenged, the BSE agent is more infectious  than the scrapie agent . A more plausible explanation is the difference in age at challenge between this experiment (6 months) and the one reported by González et al. , in which pre-weaned lambs (10–15 days old) were inoculated; this age-related susceptibility of sheep to BSE would be in agreement with previously reported experimental evidence . Also in agreement with previous studies [10, 23, 24] would be the lack of age-related susceptibility for sheep orally dosed at three or six months of age.
Romney sheep dosed with cattle BSE showed a lower involvement of LRS tissues at clinical end point compared to Suffolk sheep dosed with the same BSE source, which is in agreement with a previous study in which sheep of the same two breeds were killed sequentially at different time points after oral inoculation . However, no differences in LRS involvement between the two breeds were noted when the animals were challenged with sheep-derived BSE, suggesting some sort of adaptation of the BSE agent to replicate and accumulate in the LRS tissues of Romney sheep after sheep passage. This was actually the only effect observed that could be attributable to the source of the inoculum since in terms of minimum effective dose, ARs and STs cattle-derived BSE and the three sheep-derived BSE inocula behave similarly. Therefore, the alleged increased pathogenicity of sheep BSE compared to cattle BSE for transgenic mice expressing bovine , porcine  or human [27, 28] PrP has not been corroborated in the present study, as far as sheep recipients is concerned.
The studies presented in this report indicate that the minimum effective oral dose of BSE for ARQ/ARQ sheep is 0.05g (50mg), with an overall attack rate of ~13% (~17% for cattle- and 10% for sheep-derived inoculum). This figure contrasts with the minimum effective dose of ovine BSE for sheep of the same genotype on intracerebral inoculation, which was worked out as 0.00005g (0.05mg) tissue equivalent, with a 60% attack rate . A comparison between the two figures would suggest that the efficiency of the intracerebral route is around 103 times higher than that of oral dosing. In terms of ID50, the results from the experiments of this report provide an oral dose figure of BSE for sheep of 10−0.05, with variations between 10-.020 for Romney sheep inoculum and 100.46 for Suffolk sheep inoculum. To make these figures more comparable with those obtained in the intracerebral experiment, where Romney sheep were challenged with sheep-derived BSE , the ID50 was calculated for Romney recipients orally dosed with sheep-derived inoculum, that is, G3, 6 and 8 of the present report. This calculation provided a figure of 100.29, approximately 105 times lower than the 105.4 obtained in the intracerebral experiment. Whatever the calculation used, and allowing for possible differences in infectious titres between the inocula used in these experiments, the markedly different efficiencies between the oral and intracerebral routes 1) could explain why a proportion of ARR/ARR and ARQ/ARR sheep succumb to intracerebral BSE challenge [21, 29] while they are resistant to orally-administered BSE [10 and G5 in this experiment] and 2) highlight the need of a cautious interpretation of data obtained from intracerebral experiments when performing risk analyses and assessments.
Perhaps slightly surprising is the lack of effect of dose on survival time, which nevertheless has been documented in other studies . One possible explanation could be that the infectious agent is not homogeneously distributed in the inoculum. Thus, highly concentrated doses, such as 5g, would produce high numbers of infectious aliquots (high attack rate) while more diluted doses, such as 0.5g or 0.05g, would produce lower number of infectious aliquots (lower attack rate) but of a similar infectiousness giving rise to similar survival times. Conversely, if the infectious agent was homogeneously distributed in the inoculum, it would be anticipated that highly concentrated inocula would contain high numbers of highly infectious aliquots resulting in high attack rates and short incubation periods, while more diluted inocula would produce high numbers of less infectious aliquots resulting in similar attack rates with longer incubation periods, which was not the case in this study. With a similar rationale, an alternative explanation could perhaps arise from the mechanism of uptake of infectious agent from the digestive tract. In this case, it could be argued that highly concentrated inocula could result in the absorption of infectious units by most exposed animals (high attack rate), while diluted inocula would lead to uptake of infectious units by fewer animals (lower attack rate); in both cases, the absorbed infectious units could amplify with similar efficiency leading to clinical disease with similar incubation periods. Whichever the case, heterogeneous distribution of the infectious agent in BSE contaminated foodstuffs or mechanism of absorption in the digestive tract, these could explain why, during the BSE epidemic in the UK, the intra-herd incidence was usually low or very low despite generalized consumption of such feeds. Similarly, it could also explain why, despite what it is assumed to be a high or generalized exposure of people with susceptible PRNP genotype to BSE contaminated meat, the actual number of vCJD cases has been lower than most predictions.
Finally, the results of these experiments provide reassurance on the outcome of the sheep BSE natural transmission study previously reported . The low efficiency of maternal transmission observed in that experiment was interpreted, at least in part, as due to the fact that incubation periods of the orally dosed dams were relatively short, which meant that in most cases infected ewes only lambed once. The experiments reported here suggest that the incubation periods would have been similarly short if the ewes had been infected with lower doses than the 5g used and that, consequently, the efficiency of natural BSE transmission from dam to offspring would be similarly low regardless of the infectious dose to which the ewes are exposed. Therefore, the present results support the notion that if UK sheep were exposed to BSE-contaminated feedstuffs (as is generally accepted) and natural transmission occurred to offspring of infected dams (as previously demonstrated), it is most likely that BSE infection would not have been maintained within the National flock and would have by now disappeared.
These experiments were funded by Defra projects SE1846 and SE1945. The authors are indebted to Hugh Simmons (APHA, Weybridge) for the provision of TSE-free sheep, to the staff at ARSU (APHA, Weybridge) for husbandry, Janey Witz for assistance with statistical analyses and to Ann Dunachie and Maria Oliva for immunohistochemistry work. Critical appraisal of the manuscript by Jim Hope (APHA) is also acknowledged.
Conceived and designed the experiments: MJ SJB LG. Performed the experiments: SM GD LT SACH LA. Analyzed the data: GM SM MJ SJB LG. Contributed reagents/materials/analysis tools: SACH SJB. Wrote the paper: GM LG.
- 1. Wilesmith JW, Wells GAH (1991) Bovine Spongiform Encephalopathy. Curr Top Microbiol Immunol 172, 21–38. pmid:1810710
- 2. Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A et al. (1996) A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 347, 921–925. pmid:8598754
- 3. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, Suttie A et al. (1997) Transmission to mice indicate that ‘new variant’ CJD is caused by the BSE agent. Nature 389: 498–501. pmid:9333239
- 4. Gajdusek DC (1977) Unconventional viruses and the origin and disappearance of kuru. Science 197, 943–60. pmid:142303
- 5. Miller MW, Wild MA, Williams ES (1998) Epidemiology of chronic wasting disease in captive Rocky Mountain elk. J Wildl Dis 34, 532–8. pmid:9706562
- 6. Konold T, Moore SJ, Bellworthy SJ, Simmons HA (2008) Evidence of scrapie transmission via milk. BMC Vet Res 4: 14 pmid:18397513
- 7. Foster J, Hope J, Fraser H (1993). Transmission of bovine spongiform encephalopathy to sheep and goats. Vet Rec 133, 339–341. pmid:8236676
- 8. Stack MJ, Chaplin MJ, Clark J (2002) Differentiation of prion protein glycoforms from naturally occurring sheep scrapie, sheep-passage scrapie strains (CH1641 and SSBP1), bovine spongiform encephalopathy (BSE) cases and Romney and Cheviot breed sheep experimentally inoculated with BSE using two monoclonal antibodies. Acta Neuropathol 104, 279–286. pmid:12172914
- 9. Van Keulen LJ, Vromans ME, Dolstra CH, Bossers A, Van Zijderveld FG (2008) Pathogenesis of bovine spongiform encephalopathy in sheep. Arch Virol 153, 445–453. pmid:18092124
- 10. McGovern G, Martin S, Jeffrey M, Bellworthy SJ, Spiropoulos J, Green R et al. (2015) Influence of breed and genotype on the onset and distribution of infectivity and disease associated prion protein in sheep following oral infection with the bovine spongiform encephalopathy agent. J Comp Pathol 152: 28–40. pmid:25435510
- 11. Wells GAH, Hawkins SAC, Green RB, Austin AR, Dexter I, Spencer YI et al. (1998) Preliminary observations on the pathogenesis of experimental bovine spongiform encephalopathy (BSE)–An update. Vet Rec 142, 103–106. pmid:9501384
- 12. Buschmann A and Groschup MH (2005) Highly bovine spongiform encephalopathy-sensitive transgenic mice confirm the essential restriction of infectivity to the nervous system in clinically diseased cattle. J Infect Dis 192: 934–942. pmid:16088845
- 13. Espinosa JC, Morales M, Castilla J, Rogers M, Torres JM (2007b) Progression of prion infectivity in asymptomatic cattle after oral bovine spongiform encephalopathy challenge. J Gen Virol 88, 1379–1383.
- 14. Jeffrey M, Witz JP, Martin S, Hawkins SAC, Bellworthy SJ, Dexter GE et al. (2015) Dynamics of the natural transmission of bovine spongiform encephalopathy within an intensively managed sheep flock. Vet Res 46, 126. pmid:26511838
- 15. Stack M, González L, Jeffrey M, Martin S, Macaldowie C, Chaplin M et al. (2009) Three serial passages of BSE in sheep do not significantly affect discriminatory test results. J Gen Virol 90, 764–768. pmid:19218224
- 16. González L, Jeffrey M, Dagleish MP, Goldmann W, Sisó S, Eaton SL et al. (2012). Susceptibility to scrapie and disease phenotype in sheep: cross-PRNP genotype experimental transmissions with natural sources. Vet Res 43, 55. pmid:22748008
- 17. Saunders GC, Lantier I, Cawthraw S, Berthon P, Moore SJ, Arnold ME. (2009) Protective effect of the T112 PrP variant in sheep challenged with bovine spongiform encephalopathy. J Gen Virol 90, 2569–2574. pmid:19587133
- 18. González L, Martin S, Houston FE, Hunter N, Reid HW, Bellworthy SJ et al. (2005). Phenotype of disease-associated PrP accumulation in the brain of bovine spongiform encephalopathy experimentally infected sheep. J Gen Virol 86, 827–838. pmid:15722546
- 19. Reed L, Muench H. (1938). A simple method of estimating fifty per cent endpoints. Am J Epidemiol 27, 493–497.
- 20. González L, Pitarch JL, Martin S, Thurston L, Simmons H, Acín C et al. (2014) Influence of polymorphisms in the prion protein gene on the pathogenesis and neuropathological phenotype of sheep scrapie after oral infection. J Comp Pathol 150, 57–70. pmid:24342584
- 21. Houston F, Goldmann W, Foster J, González L, Jeffrey M, Hunter N (2015) Comparative susceptibility of sheep of different origins, breeds and PRNP genotypes to challenge with bovine spongiform encephalopathy and scrapie. PLoS ONE 10(11): e0143251 pmid:26587837
- 22. Jeffrey M, Martin S, Chianini F, Eaton S, Dagleish MP, González L (2014) Incidence of infection in Prnp ARR/ARR sheep following experimental inoculation with or natural exposure to classical scrapie. PLoS ONE 9(3): e91026. pmid:24614120
- 23. Hunter N, Houston F, Foster J, Goldmann W, Drummond D, Parnham D et al. (2012) Susceptibility of young sheep to oral infection with bovine spongiform encephalopathy decreases significantly after weaning. J Virol 86, 11856–11862. pmid:22915816
- 24. McGovern G, Martin S, Gonzalez L, Witz J, Jeffrey M (2009) Frequency and distribution of nerves in scrapie affected and unaffected Peyer's patches and lymph nodes. Vet Pathol 46, 233–40. pmid:19261634
- 25. Espinosa JC, Andréoletti O, Castilla J, Herva ME, Morales M, Alamillo E et al. (2007a) Sheep-passaged bovine spongiform encephalopathy agent exhibits altered pathobiological properties in bovine-PrP transgenic mice. J Virol 81, 835–843.
- 26. Espinosa JC, Herva ME, Andréoletti O, Padilla D, Lacroux C, Cassard H et al. (2009) Transgenic mice expressing porcine prion protein resistant to classical scrapie but susceptible to sheep bovine spongiform encephalopathy and atypical scrapie. Emerg Infect Dis 15, 1214–1221. pmid:19751582
- 27. Padilla D, Beringue V, Espinosa JC, Andreoletti O, Jaumain E, Reine F, Herzog L et al. (2011) Sheep and goat BSE propagate more efficiently than cattle BSE in human PrP transgenic mice. PLoS Pathog 7(3), e1001319. pmid:21445238
- 28. Plinston C, Hart P, Chong A, Hunter N, Foster J, Piccardo P et al. (2011) Increased susceptibility of human-PrP transgenic mice to bovine spongiform encephalopathy infection following passage in sheep. J Virol 85 1174–1181. pmid:21084466
- 29. González L, Chianini F, Martin S, Sisó L, Gibbard L, Reid HW et al. (2007). Comparative titration of experimental ovine BSE infectivity in sheep and mice. J Gen Virol 88, 714–717. pmid:17251591